Technical Analysis for BLRX - BioLineRx Ltd.

Grade Last Price % Change Price Change
D 2.73 -1.09% -0.03
BLRX closed down 1.09 percent on Wednesday, April 14, 2021, on 39 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical BLRX trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
BB Squeeze Ended Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Bollinger Band Squeeze Range Contraction -1.09%
BB Squeeze Started Range Contraction -1.09%
Outside Day Range Expansion -4.55%
Narrow Range Bar Range Contraction -4.88%
NR7 Range Contraction -4.88%
MACD Bullish Signal Line Cross Bullish -4.21%
Older End-of-Day Signals for BLRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 15 hours ago
Down 2 % about 15 hours ago
Down 1% about 15 hours ago
Up 1% about 15 hours ago
Fell Below Lower Bollinger Band about 15 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


BioLineRx Ltd. Description

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company's development pipeline consists of six clinical-stage therapeutic candidates, including BL-1020, which is in Phase II/III clarity trial to enhance cognitive function in schizophrenia patients; BL-1040, a novel polymer solution that is under pivotal CE-Mark registration trial for use in the prevention of pathological cardiac remodeling following a myocardial infarction; and BL-5010, a medical device, which has completed Phase I/II clinical trials for the non-surgical removal of skin lesions. Its development pipeline also includes BL-1021 that is in Phase Ia clinical trial for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-7040, which is in Phase II clinical trial for the treatment of inflammatory bowel disease; and BL-8040, a peptide that has completed Phase I/II clinical trial for the treatment of acute myeloid leukemia and other hematological cancers. The company also has six products in various pre-clinical development stages for indications, such as central nervous system diseases, infectious diseases, cardiovascular, and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate therapeutic candidates. BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Development Pain Infectious Diseases Autoimmune Diseases Drug Discovery Pharmacology Autoimmune Disease Clinical Research Clinical Trial Acute Myeloid Leukemia Schizophrenia Inflammatory Bowel Disease Nerve Neuropathic Pain Pivotal Central Nervous System Disease Central Nervous System Diseases Treatment Of Acute Myeloid Leukemia Hematological Cancers Compugen Infarction Jiangsu Myocardial Infarction Treatment Of Inflammatory Bowel Disease Biopharmaceutical Development Polymer Solution

Is BLRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 4.23
52 Week Low 1.4
Average Volume 1,168,982
200-Day Moving Average 2.37
50-Day Moving Average 3.11
20-Day Moving Average 2.88
10-Day Moving Average 2.83
Average True Range 0.16
ADX 20.81
+DI 11.75
-DI 22.26
Chandelier Exit (Long, 3 ATRs ) 2.73
Chandelier Exit (Short, 3 ATRs ) 3.14
Upper Bollinger Band 3.08
Lower Bollinger Band 2.69
Percent B (%b) 0.11
BandWidth 13.72
MACD Line -0.07
MACD Signal Line -0.06
MACD Histogram -0.0043
Fundamentals Value
Market Cap 58.44 Million
Num Shares 21.4 Million
EPS -2.84
Price-to-Earnings (P/E) Ratio -0.96
Price-to-Sales 0.00
Price-to-Book 1.99
PEG Ratio 0.20
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.93
Resistance 3 (R3) 2.93 2.86 2.90
Resistance 2 (R2) 2.86 2.81 2.86 2.89
Resistance 1 (R1) 2.80 2.78 2.76 2.80 2.88
Pivot Point 2.73 2.73 2.71 2.73 2.73
Support 1 (S1) 2.66 2.68 2.63 2.66 2.58
Support 2 (S2) 2.59 2.65 2.59 2.57
Support 3 (S3) 2.53 2.59 2.56
Support 4 (S4) 2.53